Webinar Technology

Part 3: Targeting Cancer Pathways: Tumor Metabolism and Proliferation

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Part 3: Targeting Cancer Pathways: Tumor Metabolism and Proliferation

Recorded 11 June 2015



Brought to you by Science and Science Signaling.

This webinar is the third in a series focusing on the cancer pathways that support tumor development, the emerging research in identifying and targeting these pathways, and innovations in the development of increasingly effective cancer therapy options. Recent advances in our understanding of cancer have revealed that the disease cannot be understood through simple analysis of genetic mutations within the cancerous cells. Instead, tumors should be considered as complex tissues in which the cancer cells communicate directly and indirectly with the surrounding cellular microenvironment and evolve traits that promote their own survival. In this webinar we will explore how cancer cells are able to reprogram their metabolic pathways to enable energy production under conditions that are disabling to most normal cells. Of particular interest are how tumor-specific metabolic changes promote oncogenic progression and how these changes can be exploited to develop more effective treatment options.

During the webinar, the speakers will:

  • Outline the major metabolic changes seen in tumor tissue
  • Explain how specific metabolic pathways can be targeted during therapeutic interventions
  • Introduce the role of autophagy and cell death in tumor survival and progression.

This webinar will last for approximately 60 minutes.

You can also view Part 1, Part 2Part 4, and Part 5 of this series.

Speaker bios

M. Celeste Simon, Ph.D.

University of Pennsylvania
Philadelphia, PA

Dr. Simon is the scientific director of the Abramson Family Cancer Research Institute (AFCRI) of the Perelman School of Medicine at the University of Pennsylvania. She received her Bachelor's degree from Miami University and completed a Ph.D. in biochemistry at Rockefeller University in 1985. She conducted postdoctoral research with Joseph Nevins at Rockefeller and then Stuart Orkin at Harvard Medical School. Dr. Simon became an assistant professor of medicine/molecular genetics and cell biology at the University of Chicago in 1992. In its first national competition, she was named an assistant investigator of the Howard Hughes Medical Institute in 1994, remaining an HHMI investigator for 20 years, until August 2014. In 1999, Dr. Simon moved to the University of Pennsylvania School of Medicine and hers was one of the founding laboratories of the newly formed AFCRI there. She was promoted to associate professor of cell and developmental biology in 1999, and full professor in 2006, becoming the scientific director of AFCRI in 2007. Dr. Simon's research is focused on how cells sense and respond to changes in the availability of molecular oxygen and nutrients. 

Nissim Hay, Ph.D.

University of Illinois
Chicago, IL

Dr. Hay obtained his Ph.D. in molecular biology and genetics at the Weizmann Institute of Science in Rehovot, Israel and carried out his postdoctoral work at the University of California, San Francisco. He was an assistant and then associate professor at the University of Chicago before moving to the University of Illinois College of Medicine in Chicago, where he is currently a distinguished university professor in the department of biochemistry and molecular genetics. The main body of his research has been to delineate the mechanisms by which the serine/threonine kinase Akt affects tumorigenesis and metabolism, both at the cellular and organismal levels. In addition, he investigates the role of glucose metabolism in cell proliferation and survival of cancer cells, and how it could be exploited for cancer therapy. Dr. Hay is on the editorial boards of the journals Molecular and Cellular Biology and Molecular Biology of the Cell, among others.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here